Background/aims: In Japan, aphthous-type Crohn's disease (type A CD) is thought to represent an early phase of Crohn's disease (CD), and diagnosis of type A CD is possible in the diagnostic criteria for CD in Japan. However, the details of type A CD are not well understood.
Methods: Subjects comprised 649 CD patients diagnosed between 1985 and 2011. The incidence of type A CD over time was clarified in two periods (1985-2004 and 2005-2011). The course of type A CD was also investigated, and cases that did and did not progress to typical CD were compared.
Results: No significant difference was seen in the incidence of type A CD between the two periods (5.2 vs. 8.5%, p = 0.125). Type A CD patients followed at our hospital progressed to typical CD at a rate of 59.3%. In comparing progressive and nonprogressive cases, the frequency of large, densely distributed aphthous lesions in the small intestine was higher among progressive cases (p = 0.018).
Conclusion: Type A CD is an early phase of CD, and CD diagnostic criteria including early cases are valid in Japan.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000350615 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Infliximab and adalimumab in the treatment of fistulizing Crohn's disease: a propensity score-matched analysis from the prospective Persistence Australian National IBD Cohort (PANIC4) study.
Am J Gastroenterol
December 2024
Department of Gastroenterology and Hepatology, Concord Repatriation General Hospital, Sydney, Australia.
Background/aims: There are spare data on comparative medication efficacy in fistulizing Crohn's disease (FCD), particularly with immunomodulator co-therapy. Persistence is a unique way to assess real-world outcomes.
Methods: The persistence of all dispensed biological agents were analysed from the Australian Pharmaceutical Benefits Scheme (PBS) registry data 2005-2021 for FCD.
Increased medication utilization precedes incidentally diagnosed inflammatory bowel disease: a multicenter, case-control study.
Am J Gastroenterol
December 2024
Gastroenterology Department, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.
This study investigates whether subclinical inflammation in asymptomatic inflammatory bowel disease (IBD) patients leads to increased medication use. In a multicenter, retrospective analysis of patients diagnosed with incidental ulcerative colitis or Crohn's disease during colorectal cancer screening (2010-2021), medication use was compared with symptomatic patients and healthy non-IBD controls. Asymptomatic patients showed a higher use of cardiovascular, antiparasitic, musculoskeletal, respiratory, and sensory organ medications up to five years before diagnosis.
View Article and Find Full Text PDFDeconditioning in quiescent Crohn's Disease patients with heightened fatigue perception.
J Crohns Colitis
January 2025
Professor of Gastroenterology, Translational Medical Sciences, School of Medicine, Faculty of Medicine and Health Sciences, University of Nottingham; NIHR Nottingham Biomedical Research Centre, Nottingham.
Background & Objective: IBD fatigue aetiology is poorly understood. This study quantified body composition and physical function alongside proton magnetic resonance imaging (1H MRI) and spectroscopy (31P MRS) measures of organ structure and function in quiescent Crohn's Disease patients (CD) and healthy volunteers (HV), to identify a physiological basis for IBD fatigue.
Methods: Body composition was determined using DEXA and 1H MRI.
Inflammatory bowel disease vs strongyloidiasis.
Rev Esp Enferm Dig
January 2025
Digestive Medicine, Hospital Clínico Universitario de Valencia .
We report the case of a 38-year-old woman with a 10-year history of ulcerative proctosigmoiditis. Two months after traveling to Morocco, she developed gastrointestinal symptoms accompanied by eosinophilia in blood tests. Four months later, she progressed to systemic illness with pulmonary involvement.
View Article and Find Full Text PDFCombination treatment risankizumab and subcutaneous infliximab for refractory Crohn's disease.
Rev Esp Enferm Dig
January 2025
Inflamatory Bowel Disease Unit, Hospital Universitario Basurto, España.
We present the case of an 18-year-old male who was diagnosed at age 15 with extensive ileal and colonic Crohn's disease with rectal involvement and associated perianal fistula. The patient received different treatments with biologics withouth achieving response, so we decide to try combination therapy with subcutaneous Infliximab and Risakizumab. The patient showed improvement at second week, achieving both analytical, clinical and endoscopic response .
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!